Table 2

Literature review – patient characteristics, treatment and outcomes – abbreviations and reference list

Name (Country)

Year

n

Pathology (number of cases)

Successful non-operative biopsy

Resection

Chemotherapy

Radiotherapy

Outcome without resection, chemotherapy or RT

Outcomes with resection

Outcomes with chemotherapy without resection or RT

Outcomes with chemotherapy and RT without resection


Hart USA

1987

14

Histiocytcic (9)

Poorly diff lymphocytic (2)

Well diff lymphocytic (1)

T cell (1)

Undifferentiated (1)

0 of 14

1 of 14

CHOP (14)

1 of 14

0

1 NR

(Received CHOP, RT NR)

6 alive at mean 32 months (18–48 months)

2 died within 3 months

5 died at mean 35 months (6–108)

(5 of 13 received RT)

Webb USA

1989

2**

DLBCL (6)

Follicular mixed (2)

Small cleaved (1)

1 of 2

MACOP-B (1)

0 of 2

0

1 alive at 95 months

(Received CAMEL, 0 RT)

1 alive at 21 months

0

Mansour England

1989

12

NR

0 of 12

1 of 12

CHOP (9)

5 of 12

2 died in post-op period after bypass

1 NR

(Received chemo, RT NR)

4 alive at 3,36,48,84 months

5 died at 2–11 months

(5 of 9 received RT)

Tuchek USA

1993

7

NR

0 of 7

0 of 7

CHOP (1)

CVP (1)

CAMEL (1)

0 of 7

4 died – mean survival 5 months

0

3 alive at 60,72,96 months

0

Behrns USA

1994

12

DLBCL (7)

Small cleaved (2)

Mixed (3)

4 of 12

1 of 12

CHOP (4)

4 of 12

2 relapsed or died (NR)

1 NR

(Received chemo, RT NR)

2 died – mean survival 13 months

3 died – mean survival 26 months

(5 died after RT only – mean survival 22 months)

Ezzat Saudi Arabia

1996

5

DLBCL (5)

2 of 5

1 of 5

CHOP (4)

CHOP- Bleo (1)

2 of 5

0

1 alive at 23 months

(Received CHOP, 0 RT)

2 alive at 24,24 months

2 alive at 30,84 months

Bouvet USA

1997

11

DLBCL (10)

Mixed follicular (1)

6 of 11

3 of 11

See legend*

7 of 11

0

3 alive at 11,13,23 months

(All received CHOP, OPEN or CHOP-Bleo, 0 RT)

1 alive at 191 months

4 alive at 44,55,67,159 months

3 died at 12,16,80 months

Koniaris USA

2000

8

DLBCL (7)

Mixed follicular (1)

3 of 8

3 of 8

CHOP (6)

MACOP-B (1)

5 of 8

0

3 alive at 53,62,64 months

(2 received CHOP and RT)

1 alive at 24 months

2 alive at 51,128 months

2 died at 9,37 months

Nishimur a Japan

2001

19

DLBCL (9)

B Immunocytoma (2)

B follicular (2)

T peripheral (3)

T anaplastic large (1)

2 of 19

10 of 19

CHOP (5)

Mitomycin (1)

Tegafur (1)

Unspecified chemo (1)

0 of 19

7 died at 1,2,2,3,8,60,72 months

4 died at 9,10,11,27 months

4 alive at 3,4,12,19 months

2 ND

(6 received chemo, 4 no chemo, 0 RT)

2 died at 2,8 months

0

Nayer USA

2004

8

DLBCL (4)

High grade B cell (1)

Low grade B (2)

Suspicious (1)

8 of 8

0 of 8

Chemo (4)

Chemo and auto SCT (2)

NR (2)

3 of 8

(2 NR)

0

0

3 alive at 5,6,76 months

3 alive at 2,7,72 months

Arcari Italy

2005

5

DLBCL (3)

Lymphoplasmacytic (2)

3 of 5

2 of 5

CVP/CHO

P (3)

CHOP (1)

CVP (1)

2 of 5

0

1 alive at 160 months

1 died at 8 months

(Received CHOP or CVP, 0 RT)

1 alive at 60 months

2 died at 67, 88 months

(2 of 3 received RT)

Grimison Australia [current series]

2005

4

DLBCL (3)

Follicular (1)

1 of 4

0 of 4

CHOP (2)

Rituximab- CHOP (1)

CVP (1)

4 of 4

0

0

0

1 died 32 months

3 alive 15,25,64 months

Overall

107 cases inc. current series

    Excluding 2 NR:

29 of 105

23 of 107

80 of 107

    Excluding 2 NR:

33 of 105

    Excluding 2 NR:

0% (0 of 15) NED

Mean 13 months

2YS 13% (2 of 15)

    Excluding 5 NR:

72% (13 of 18) NED

Mean 34 months

2YS 33% (6 of 18)

57% (36 of 63) NED

Mean 38 months

2YS of 62% (28 of 45) –

    excludes 18 NR


*CHOP (1), CHOP-Bleomycin (2), CHOP-OPEN (2), CHOP-Bleomycin, CMED, ESHAP (1), CHOP-Bleomycin, OPEN (1), CHOP, OAP-Bleomycin, MIME (1), CHOP-Bleomycin, MINE, ESHAP, Autologous SCT (1), IM-Etop, HOP (1), ESHAP, BACOS, MIME (1)

**excludes 7 patients with stage III/IV NHL

BACOS – bleomycin, doxorubicin, cyclophosphamide, vincristine, methylprednisolone

CAMEL – cyclophophamide, adriamycin, vincristine, prednisone Chemo – chemotherapy

CHOP – cyclophosphamide, doxorubicin, vincristine, prednisone

CMED – cyclophosphamide, methotrexate, etoposide, dexamethasone

CVP – cyclophosphamide, vincristine, prednisone

DLBCL – diffuse large Bcell lymphoma

ESHAP – etoposide, methyprednisolone, high-dose cytarabine, cisplatin

HOP – doxorubicin, vincristine, prednisone

IM-etop – ifosfamide, methotrexate, etoposide

MACOP-B

MIME – MESNA, ifosfamide, methotrexate, etoposide

MINE – MESNA, ifosfamide, mitoxantrone, etoposide

NED – no evidence of disease

NR – not reported

OAP-Bleomycin – vincristine, cytarabine, prednisone, bleomycin

OPEN – vincristine, prednisone, etoposide, mitoxantrone

RT – radiotherapy

SCT – stem cell transplantation

References for table 2 – Hart[12], Webb[22], Mansour.[45], Tuchek[47], Behrns.[2], Ezzat[48], Bouvet.[21], Koniaris[23], Nishimura[49], Nayer.[3], Arcari[20]

Grimison et al. BMC Cancer 2006 6:117   doi:10.1186/1471-2407-6-117

Open Data